Symptoms

ADD COLOR EyeDear Announces the Launch of the Next-Gen Wearable Eye Care Device on Kickstarter

Retrieved on: 
Friday, July 30, 2021
Human–computer interaction, Periorbital dark circles, Symptoms, Distributed computing architecture, Wearable devices, Smartwatches, Ubiquitous computing

EyeDear is a smart wearable eye care device that delivers eye care that can eliminatefatigue and dark circles.

Key Points: 
  • EyeDear is a smart wearable eye care device that delivers eye care that can eliminatefatigue and dark circles.
  • EyeDear is now available on Kickstarter: https://bit.ly/2WeZbtV
    EyeDear is the next-generation wearable eye care device, made for eye beauty and relaxation.
  • The EyeDear with EMS, heat, and red light technology can helpto relieve eye fatigue, eye strain, and dryness.
  • It is the perfect eye care device for daily use and is available now on Kickstarter with special offers available for early backers.

Neosensory partners with Oaktree Products to distribute new tinnitus program, Neosensory Duo, to US audiologists

Retrieved on: 
Tuesday, July 13, 2021
Branches of biology, Neuroscience, Medical specialties, Audiology, Occupational safety and health, Neurophysiology, Auditory perception, Symptoms, Tinnitus, Neuroplasticity

Neosensory has been developing innovative hearing and sensory augmentation solutions since 2015 and was recently recognized by Fast Company's 2021 World Changing Ideas Awards.

Key Points: 
  • Neosensory has been developing innovative hearing and sensory augmentation solutions since 2015 and was recently recognized by Fast Company's 2021 World Changing Ideas Awards.
  • This proprietary, non-invasive method known as bimodal stimulation leverages neuroplasticity and has been shown to reduce tinnitus symptoms in more than 87% of users.
  • For more information about Neosensory and its products, contact Neosensory at [email protected] or visit https://neosensory.com .
  • The company's tinnitus program, Neosensory Duo, launched in March 2021, is based on new scientific research on bimodal stimulation.

Neuromod research reveals that more than three in four UK tinnitus sufferers have never received treatment for their condition

Retrieved on: 
Tuesday, July 13, 2021
Audiology, Otorhinolaryngology, Auditory perception, Health sciences, Medicine, Occupational safety and health, Symptoms, Tinnitus, American Tinnitus Association, Tinnitus masker

The poll also revealed that 67% of UK tinnitus sufferers don't feel adequately informed about their condition.

Key Points: 
  • The poll also revealed that 67% of UK tinnitus sufferers don't feel adequately informed about their condition.
  • The research, which polled 251 people with tinnitus across the UK, found that 76.1% of respondents have never used any form of tinnitus treatment.
  • This may stem from the fact that so many people with tinnitus never seek any form of treatment for it.
  • The Lenire tinnitus treatment device is available to people with tinnitus through The Tinnitus Clinic's network of seven locations across the UK or online via the company's Neuromod Medical tinnitus telemedicine service.

Auris Medical Reaches Midpoint for Enrollment in Part B of AM-125 Phase 2 TRAVERS Trial in Acute Peripheral Vertigo

Retrieved on: 
Friday, May 14, 2021
Health sciences, Clinical medicine, Medicine, Audiology, Occupational safety and health, Auditory perception, Symptoms, Tinnitus, XC2, Ear, Nasal administration, Auris

They are randomized to receive either 10 or 20 mg of intranasal betahistine or a placebo three times daily for four weeks.

Key Points: 
  • They are randomized to receive either 10 or 20 mg of intranasal betahistine or a placebo three times daily for four weeks.
  • \xe2\x80\x9cWe look forward to completing the TRAVERS trial later in 2021 and to advancing the AM-125 program further.
  • There is a strong medical need for a novel drug in this area, with e.g.
  • In addition, Auris Medical has two Phase 3 programs under development: Sonsuvi\xc2\xae (AM-111) for acute inner ear hearing loss and Keyzilen\xc2\xae (AM-101) for acute inner ear tinnitus.

Five Tips to Manage Tinnitus and Inner Ear Ringing Symptoms

Retrieved on: 
Monday, April 26, 2021
Audiology, Occupational safety and health, Otorhinolaryngology, Health sciences, Branches of biology, Auditory perception, Symptoms, Tinnitus, Auditory system, Hearing loss, Ear, Tinnitus retraining therapy

b'CHATTANOOGA, Tenn., April 26, 2021 /PRNewswire/ -- Tinnitus is a medical condition marked by incessant inner ear ringing and similar sounds, impacting more than 50 million Americans .

Key Points: 
  • b'CHATTANOOGA, Tenn., April 26, 2021 /PRNewswire/ -- Tinnitus is a medical condition marked by incessant inner ear ringing and similar sounds, impacting more than 50 million Americans .
  • and Lipo-Flavonoid Chief Audiologist, has seen more cases of tinnitus emerge in the past year, resulting from the COVID-19 pandemic.
  • "Increased ear ringing and hearing loss is often more prevalent during the winter months as there\'s a greater likelihood for flu-related congestion and sinus infections," says Borgia.
  • If you\'re newly experiencing tinnitus, Dr. Borgia has compiled the following tips to help manage symptoms and protect your hearing:\nModify your medications.

PharmaNutra S.p.A.: A Targeted Nutritional Supplement Proves To Aid Persistent Fatigue In Post-Covid Patients

Retrieved on: 
Monday, April 12, 2021
Exercise physiology, Fatigue, Subjective experience, Symptoms, Branches of biology, Clinical medicine, Cancer-related fatigue, Medicine, Effects of fatigue on safety

b"PISA, Italy, April 12, 2021 /PRNewswire/ -- Fatigue is one of the most common symptoms lasting for months after the infection.

Key Points: 
  • b"PISA, Italy, April 12, 2021 /PRNewswire/ -- Fatigue is one of the most common symptoms lasting for months after the infection.
  • It is made up of 13 statements relating to ability to perform everyday tasks, sleep needs during the day, energy and tiredness.\nA second questionnaire created by re-adapting the Chalder Fatigue Scale was used to assess mental fatigue.
  • The score indicating their fatigue improved by 64%.
  • Any differences among sexes was investigated and women suffered 'more severe' initial fatigue while showing a greater improvement in terms of mental fatigue.

Half of Kids with Inflammatory Syndrome After COVID-19 Have Neurologic Symptoms

Retrieved on: 
Saturday, April 17, 2021
Signs and symptoms, Symptoms, Neurological disorders, Branches of biology, Clinical medicine, Medicine, Autoimmune diseases, Encephalitis

"We found that many children experienced neurologic symptoms involving both the central and peripheral nervous systems.

Key Points: 
  • "We found that many children experienced neurologic symptoms involving both the central and peripheral nervous systems.
  • Of those, 24 children had neurologic symptoms or signs that they had not experienced previously.
  • In addition, three children had problems with their peripheral nerves and one child had seizures.\nThe children with neurologic symptoms were more likely to need a ventilator and drugs to help stabilize their blood circulation than the children without neurologic symptoms.
  • However, there were no differences in terms of demographics, inflammatory markers, management or short-term outcomes between the two groups.\n"Children who develop this condition should definitely be evaluated for neurologic symptoms and longer- term cognitive outcomes," said Abdel-Mannan.

Claritas to Expand R-107 Program to Include Treatment of Sepsis, the Leading Cause of Death in COVID-19 Patients

Retrieved on: 
Thursday, April 8, 2021
Medicine, Health, Clinical medicine, Influenza, Influenza-like illness, Symptoms, Syndromes, COVID-19, Infection

Claritas is currently developing R-107 for the treatment of viral infections, including vaccine-resistant COVID-19.

Key Points: 
  • Claritas is currently developing R-107 for the treatment of viral infections, including vaccine-resistant COVID-19.
  • A control group consisted of 13 sheep that were treated with an intramuscular injection of saline.
  • Most COVID-19 infections cause mild to moderate illness with respiratory and flu-like symptoms, including fever, chills, cough and sore throat.
  • Claritas Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company focused on developing and commercializing therapies for patients with significant unmet medical needs.

 Olive Union Raises $20M to Expand into Digital Hearing Therapeutics

Retrieved on: 
Monday, April 5, 2021
Audio, Video, Hardware, Health, Medical devices, Consumer electronics, Technology, Mobile, Wireless, Other Technology, Audiology, Occupational safety and health, Otorhinolaryngology, Health sciences, Medical specialties, Sound, Auditory perception, Symptoms, Tinnitus, Hearing aid, Hearing

Olive Union - the company making smarter hearing health a reality for everyone - today announced the closing of a $7M Series B.

Key Points: 
  • Olive Union - the company making smarter hearing health a reality for everyone - today announced the closing of a $7M Series B.
  • With the current round and cumulative $20M in lifetime funding, Olive plans to expand beyond its existing hearing aids product line into new digital therapeutics for tinnitus and overall hearing health, and begin laying the foundation for its next generation of smart hearing technology.
  • Collective exposure to prolonged and nearby loud noises has put us in the middle of an unprecedented decline in global hearing health, said Olive Union Founder and CEO, Owen Song.
  • Olive Union blends cutting-edge technology, modern design, and an intuitive user experience to offer affordable hearing for all.

Otonomy Initiates Phase 2 Clinical Trial of OTO-313 in Tinnitus

Retrieved on: 
Thursday, March 25, 2021
Medicine, Audiology, Health sciences, Clinical medicine, Auditory perception, Occupational safety and health, Mind–body interventions, Symptoms, Tinnitus, Placebo, Tinnitus retraining therapy

The randomized, double-blind, placebo-controlled Phase 2 study will enroll approximately 140 patients with persistent, early onset tinnitus of at least moderate severity.

Key Points: 
  • The randomized, double-blind, placebo-controlled Phase 2 study will enroll approximately 140 patients with persistent, early onset tinnitus of at least moderate severity.
  • The Phase 2 trial will be conducted at approximately 50 clinical sites in the U.S. and Europe.
  • In 2020, we reported positive results from a Phase 1/2 trial of OTO-313 in patients with unilateral tinnitus of at least moderate severity.
  • This trial demonstrated a positive clinical response for OTO-313 using the Tinnitus Functional Index (TFI) that was correlated with improvements in tinnitus loudness, tinnitus annoyance and patient global impression of change measures.